| Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908) |
|---|
| 09/12/2002 | WO2002070562A2 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | WO2002070561A2 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | WO2002070560A2 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | WO2002070559A2 Nuclear hormone receptor ligand binding domains |
| 09/12/2002 | WO2002070558A2 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | WO2002070557A2 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | WO2002070511A1 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
| 09/12/2002 | WO2002070502A1 Dimeric isoflavones |
| 09/12/2002 | WO2002070479A1 N-4-piperidinyl compounds as ccr5 modulators |
| 09/12/2002 | WO2002069994A2 Combined use of derivatives of glp-1 analogs and ppar ligands |
| 09/12/2002 | WO2002069930A1 Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| 09/12/2002 | WO2002069886A2 Modified proteins, designer toxins, and methods of making thereof |
| 09/12/2002 | WO2002057409A3 Antisense modulation of src-2 expression |
| 09/12/2002 | WO2002022132A3 Novel topical oestroprogestational compositions with systemic effect |
| 09/12/2002 | WO2002012346A3 A new slit-like protein obtained from a cdna library from hs-5 stromal cell line |
| 09/12/2002 | WO2001089520A3 Dehydroascorbic acid formulations and uses thereof |
| 09/12/2002 | WO2001085175A3 Prevention of insulin-dependent diabetes, complications thereof, or allograft rejection by inhibition of cyclooxygenase-2 activity with ns398 or pdtc |
| 09/12/2002 | WO2001047562A3 Hydrolytically degradable carbamate derivatives of poly(ethylene glycol) |
| 09/12/2002 | WO2001034126A9 Mesoprogestins (progesterone receptor modulators) as a component of compositions for hormone replacement therapy (hrt) |
| 09/12/2002 | US20020128306 Programmed cell death; expansion of hematopoietic cells, for prolonging viability of an organ for transplantation, and maintaining viability of cell lines used in bioproduction |
| 09/12/2002 | US20020128289 Insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action |
| 09/12/2002 | US20020128265 CRF receptor antagonists and methods relating thereto |
| 09/12/2002 | US20020128259 Using a vasopressin antagonist such as conivaptan |
| 09/12/2002 | US20020128246 Regulation of intracellular glucocorticoid concentrations |
| 09/12/2002 | US20020128245 Using a 11 beta-reductase inhibitor in the manufacture of a medicament for control of 11-keto steroid conversion to 11 beta-hydroxysteroid in vivo |
| 09/12/2002 | US20020128244 Regulation of intracellular glucocorticoid concentrations |
| 09/12/2002 | US20020128240 Treatment of hyperproliferative diseases using active vitamin D analogues |
| 09/12/2002 | US20020128220 Testosterone-repressed prostate message-2 (TRPM-2); delaying progression of prostatic tumor cells to an androgen-independent state |
| 09/12/2002 | US20020127668 Polypeptide for use in the diagnosis and treatment of cancer, nervous system and vessicular transport disorders |
| 09/12/2002 | US20020127221 Urocortin proteins and uses thereof |
| 09/12/2002 | US20020127198 Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| 09/12/2002 | US20020127188 Composition for pulmonary administration comprising a drug and a hydrophobic amino acid |
| 09/12/2002 | US20020127185 Pharmaceutical aerosol formulations containing fluoroalkanes and budesonide |
| 09/12/2002 | CA2440642A1 Dimeric isoflavones |
| 09/12/2002 | CA2439941A1 Secreted proteins |
| 09/12/2002 | CA2439594A1 Interleukin-8 homologous polypeptides and therapeutic uses thereof |
| 09/12/2002 | CA2439205A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439203A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439200A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439197A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439196A1 Nuclear hormone receptor ligand binding domains |
| 09/12/2002 | CA2439195A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439192A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2438326A1 Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| 09/12/2002 | CA2437594A1 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
| 09/11/2002 | EP1237904A2 14,15-beta-methylene substituted androgens |
| 09/11/2002 | EP1237903A1 11-beta-phenylestradiene derivatives with fluoroalkyl groups in the aromatic side chain, production thereof and pharmaceutical compositions containing these compounds |
| 09/11/2002 | EP1237902A1 Halogenated sulphamate-, phosphonate-, thiophosphonate-, sulphonate- and sulphonamide- compounds as inhibitors of steroid sulphatase |
| 09/11/2002 | EP1237898A2 N?6 heterocyclic 8-modified adenosine derivatives |
| 09/11/2002 | EP1237891A1 Heterocyclic dihydropyrimidines as potassium channel inhibitors |
| 09/11/2002 | EP1237857A1 New phenalkyloxy-phenyl derivatives |
| 09/11/2002 | EP1237856A1 New tri-substituted phenyl derivatives and analogues |
| 09/11/2002 | EP1237855A1 Crystalline form of (s)-2 ethoxy-3- 4-(2- 4-methanesulfonyloxyphenyl ethoxy) phenyl] propanoic acid |
| 09/11/2002 | EP1237854A1 Comminuted form of (s)-2-ethoxy -3- 4-(2- 4-methanesulfonyloxyphenyl ethoxy) phenyl] propanoic acid |
| 09/11/2002 | EP1237582A2 Methods for introducing genes into mammalian subjects |
| 09/11/2002 | EP1237575A1 Tnf-alpha antagonist and lfa-1 antagonist for treating lfa-1 or tnf-alpha mediated disorder |
| 09/11/2002 | EP1237565A1 Betaglycan as an inhibin receptor and uses thereof |
| 09/11/2002 | EP1237556A2 Pharmaceutical implant containing immediate-release and sustained-release components and method of administration |
| 09/11/2002 | EP1237537A1 Composition in the form of a gel for receiving an active ingredient in a solution or suspension, especially for application on a mucous membrane and method of production thereof |
| 09/11/2002 | EP1003490B1 Transdermal therapeutic system (tts) for administering sexual steroid hormones |
| 09/11/2002 | EP0871467B1 Formulation for peptide release |
| 09/11/2002 | EP0799206B1 Aryl- and hetaryl-sulfonamide derivatives, their preparation and their use as endothelin antagonists |
| 09/11/2002 | CN1368975A Organosilyl compounds having nuclear hormone receptor modulating activity |
| 09/11/2002 | CN1368879A Use of (-)(3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance type 2 diabetes, hyperlipidemia and hyperuricemia |
| 09/11/2002 | CN1368372A Xiaoying pil and its preparing process |
| 09/11/2002 | CN1368158A Nano medicine 'Jiakangling' and its preparing process |
| 09/11/2002 | CN1368155A Nano medicine 'Huanshao' and its preparing process |
| 09/11/2002 | CN1368112A Nano medicine 'Yishenling' and its preparing process |
| 09/10/2002 | US6448285 Disorders associated with overactivity of 5 alpha reductase; androgen dependent disorders such as seborrhoea, acne, hirsutism and/or androgenic alopecia |
| 09/10/2002 | US6448263 Synthesis routes for such as 2-amino-n-(2-(3a-(r)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo -(4,3-c) pyridin-5-yl)-1-(r)-benzyloxymethyl-2-oxo-ethyl)-isobutyramide l-tartaric acid salt |
| 09/10/2002 | US6447785 Method for treating hypercalcemia |
| 09/10/2002 | US6447783 Compositions comprising FGF9 and use thereof for stimulating cartilage and bone repair |
| 09/06/2002 | WO2002068461A2 Heterocarpine, a human ghrh-binding protein |
| 09/06/2002 | WO2002068427A1 Tricyclic quinolinone and tricyclic quinoline as androgen receptor modulator compounds |
| 09/06/2002 | WO2002068420A1 Xanthine derivative, production and use thereof as a medicament |
| 09/06/2002 | WO2002068415A1 Pyrazole compounds useful as protein kinase inhibitors |
| 09/06/2002 | WO2002068410A1 Substituted pyrimidinone derivatives as ligands of integrin receptors |
| 09/06/2002 | WO2002067989A1 Crystallisation-resistant aqueous growth hormone formulations |
| 09/06/2002 | WO2002067939A1 Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| 09/06/2002 | WO2002067917A1 Compositions and methods for enhancing drug delivery across and into ocular tissues |
| 09/06/2002 | WO2002067906A1 Coating and binding agent for pharmaceutical formulations with improved storage stability |
| 09/06/2002 | WO2002067893A2 Pharmaceutical formulation comprising bicalutamide |
| 09/06/2002 | WO2002067873A2 Method for suppressing reduction of elasticity of skin |
| 09/06/2002 | WO2002043648A8 Compounds active at the glucocorticoid receptor ii |
| 09/06/2002 | WO2002040517A3 M. tuberculosis chaperonin 60.1 and uses thereof |
| 09/06/2002 | WO2002040037A3 M. tuberculosis chaperonin 60.1 and uses thereof |
| 09/06/2002 | WO2002008449A3 Ho-1 suppressor as a diagnostic and prognostic test for dementing diseases |
| 09/06/2002 | WO2001082910A3 Combination of progesterone and mifepristone for cancer therapy |
| 09/06/2002 | WO2001032614A9 Novel genes tzap7/a, tzap7/b and tzap7 involved in t cell activation and uses thereof |
| 09/06/2002 | WO2001031021A9 Multiple sclerosis-related superantigen |
| 09/06/2002 | CA2439366A1 Pharmaceutical formulation comprising bicalutamide |
| 09/06/2002 | CA2439265A1 Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| 09/06/2002 | CA2438784A1 Compositions and methods for enhancing drug delivery across and into ocular tissues |
| 09/06/2002 | CA2437516A1 Heterocarpine, a human ghrh-binding protein |
| 09/06/2002 | CA2434727A1 Tricyclic quinolinone and tricyclic quinoline as androgen receptor modulator compounds |
| 09/05/2002 | US20020123521 Such as triiodothyroacetic acid, triiodopropionic acid, 4-(2,6-dibromo-4-(1H-tetrazol-5-ylmethyl)-phenoxy)-2-isopropyl-phenol, and 4-(4-hydroxymethyl-2,6-diiodophenoxy)-2-iodo-phenol |
| 09/05/2002 | US20020123512 Pharmaceutical composition |
| 09/05/2002 | US20020123141 Recovering embryonic-like stem cells from a placenta; obtain placenta, drain cord blood, flush placenta with anticoagulant solution, recover cells |
| 09/05/2002 | US20020123102 Nucleotide sequences coding polypeptide for use in the diagnosis and treatment of thyroid defcets |
| 09/05/2002 | US20020123099 Highly expressible genes |